LAUSANNE, Switzerland, (BUSINESS WIRE) -- ADC Therapeutics SA /zigman2/quotes/214411413/composite ADCT +5.60% , a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, announced today that its executives will be participating in a fireside chat at the BofA Securities 2022 Healthcare Conference on Tuesday, May 10, 2022, at 1:40 pm ET.
A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics’ website, ir.adctherapeutics.com . A replay of the webcast will be available for approximately 30 days.
About ADC Therapeutics
ADC Therapeutics /zigman2/quotes/214411413/composite ADCT +5.60% is a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs). The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.
ADC Therapeutics’ CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large b-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents. Cami (camidanlumab tesirine) is being evaluated in a pivotal Phase 2 trial for relapsed or refractory Hodgkin lymphoma and in a Phase 1b clinical trial for various advanced solid tumors. In addition to ZYNLONTA and Cami, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.
ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit https://adctherapeutics.com/ and follow the Company on Twitter and LinkedIn .
ZYNLONTA [®] is a registered trademark of ADC Therapeutics SA.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220504005296/en/
SOURCE: ADC Therapeutics SA
+44 7879 627205 Amanda Hamilton
+1 917-288-7023 EU Media
+41 (0) 43 268 3231 USA Media
Mary Ann Ondish
Is there a problem with this press release? Contact the source provider Comtex at email@example.com. You can also contact MarketWatch Customer Service via our Customer Center.
Copyright Business Wire 2022